MYC and prostate carcinoma: MYC functions as a central regulator of glutamine metabolism in prostate cancer by repressing miR-23a/b, thereby relieving the inhibition of mitochondrial GLS and promoting glutaminolysis, particularly in androgen-independent PC-3 cells (36, 37).